Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small ...

A Penn Medicine study has shown that tailoring chemotherapy doses based on genetic testing can significantly improve safety ...

The FDA has granted accelerated approval to zongertinib for pretreated, HER2+ non-squamous NSC lung cancer, based on results ...

The FDA has granted accelerated approval to Modeyso™ (dordaviprone) as the first treatment for recurrent H3 K27M-mutant ...

The FDA has accepted Bristol Myers Squibb’s Priority Review application for Breyanzi® (lisocabtagene maraleucel) as a ...

The FDA has granted priority review for the epcoritamab combination, with potential approval making it the first bispecific antibody regimen for second-line follicular lymphoma treatment. Epkinly ...

CLD-201 (SuperNova), a novel stem cell–based oncolytic virus therapy, has received FDA Fast Track designation for soft tissue sarcoma—marking a pivotal step in its clinical development.